Gt biopharma's trike™ interim clinical trial results presented at innate killer summit 2021

Beverly hills, calif., march 29, 2021 /prnewswire/ -- gt biopharma, inc. (nasdaq: gtbp), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the company's proprietary nk cell engager (trike™) protein biologic technology platform is pleased to announce that dr. jeffrey s.
GTBP Ratings Summary
GTBP Quant Ranking